Cost-effectiveness of sleeping sickness elimination campaigns in five settings of the Democratic Republic of Congo.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
25 02 2022
25 02 2022
Historique:
received:
12
04
2021
accepted:
28
01
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Gambiense human African trypanosomiasis (gHAT) is marked for elimination of transmission by 2030, but the disease persists in several low-income countries. We couple transmission and health outcomes models to examine the cost-effectiveness of four gHAT elimination strategies in five settings - spanning low- to high-risk - of the Democratic Republic of Congo. Alongside passive screening in fixed health facilities, the strategies include active screening at average or intensified coverage levels, alone or with vector control with a scale-back algorithm when no cases are reported for three consecutive years. In high or moderate-risk settings, costs of gHAT strategies are primarily driven by active screening and, if used, vector control. Due to the cessation of active screening and vector control, most investments (75-80%) are made by 2030 and vector control might be cost-saving while ensuring elimination of transmission. In low-risk settings, costs are driven by passive screening, and minimum-cost strategies consisting of active screening and passive screening lead to elimination of transmission by 2030 with high probability.
Identifiants
pubmed: 35217656
doi: 10.1038/s41467-022-28598-w
pii: 10.1038/s41467-022-28598-w
pmc: PMC8881616
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1051Informations de copyright
© 2022. The Author(s).
Références
PLoS Negl Trop Dis. 2020 Oct 16;14(10):e0008270
pubmed: 33064783
PLoS Negl Trop Dis. 2017 Jan 5;11(1):e0005162
pubmed: 28056016
Med Ref Serv Q. 2020 Jan-Mar;39(1):67-74
pubmed: 32069199
Pharmacoeconomics. 2000 May;17(5):479-500
pubmed: 10977389
Acta Trop. 2015 Oct;150:4-13
pubmed: 26056739
Value Health. 2016 Dec;19(8):929-935
pubmed: 27987642
PLoS Negl Trop Dis. 2015 Aug 12;9(8):e0003822
pubmed: 26267814
Emerg Infect Dis. 2021 Aug;27(8):2144-2153
pubmed: 34287133
PLoS Comput Biol. 2021 Jan 29;17(1):e1008532
pubmed: 33513134
Parasit Vectors. 2015 Oct 22;8:532
pubmed: 26490248
Lancet Glob Health. 2017 Jan;5(1):e69-e79
pubmed: 27884709
PLoS Negl Trop Dis. 2020 Dec 14;14(12):e0008832
pubmed: 33315896
BMC Med. 2021 Apr 1;19(1):86
pubmed: 33794881
PLoS Negl Trop Dis. 2015 Aug 12;9(8):e0003727
pubmed: 26267667
Trans R Soc Trop Med Hyg. 2021 Mar 6;115(3):245-252
pubmed: 33611586
Bull World Health Organ. 1994;72(3):429-45
pubmed: 8062401
J Infect Dis. 2020 Feb 3;221(4):561-565
pubmed: 31565733
Clin Infect Dis. 2018 Jun 1;66(suppl_4):S286-S292
pubmed: 29860287
Trends Parasitol. 2018 Mar;34(3):197-207
pubmed: 29396200
Lancet. 2017 Nov 25;390(10110):2397-2409
pubmed: 28673422
PLoS Negl Trop Dis. 2017 Nov 13;11(11):e0006060
pubmed: 29131822
Bull World Health Organ. 2004 Sep;82(9):683-8
pubmed: 15628206
Wkly Epidemiol Rec. 2006 Feb 24;81(8):71-80
pubmed: 16673459
PLoS Negl Trop Dis. 2017 Jul 27;11(7):e0005792
pubmed: 28750007
Parasit Vectors. 2008 Feb 12;1(1):3
pubmed: 18275594
J Infect Dis. 2020 Jun 11;221(Suppl 5):S539-S545
pubmed: 31876949
PLoS One. 2018 Sep 21;13(9):e0204335
pubmed: 30240406
Med Decis Making. 2002 Jul-Aug;22(4):290-308
pubmed: 12150595
PLoS Negl Trop Dis. 2020 May 21;14(5):e0008261
pubmed: 32437391
Parasit Vectors. 2020 Aug 14;13(1):419
pubmed: 32795375